Nyxoah SA (NYXH)

Nyxoah is a Belgian medical-device company with one product: Genio, an implant about the size of a pacemaker that sits under the skin and sends small electrical pulses to the muscles in your airway when you are asleep. The idea is simple. Obstructive sleep apnea happens when muscles in the throat relax and block breathing. If you send the right electrical signal at the right time, those muscles stay open. The person sleeps without interruption. Nyxoah believes it has found a better way to treat sleep apnea than existing options, and has bet its entire company on selling Genio to patients and hospitals worldwide.

Why sleep apnea matters and why it is still hard to treat

Obstructive sleep apnea is common. In developed countries, one in twenty adults has it to a degree that disrupts their sleep and harms their health. The condition means your breathing repeatedly stops and starts during the night as your airway collapses. Your body wakes up—sometimes dozens of times an hour—to gasp and restart. You feel exhausted. Your heart works harder. Over years it raises the risk of heart attack, stroke, and sudden death.

The standard treatment is CPAP: a mask over your nose or mouth connected to a machine that pumps pressurized air into your lungs while you sleep. It works. But many people hate it. The mask is uncomfortable, the machine is noisy, and wearing it night after night takes discipline. A lot of people start CPAP and quit within months. Others use it inconsistently. The result is that plenty of people with sleep apnea either go untreated or search for an alternative.

Surgery is another option—removing tissue from the back of the throat, repositioning the jaw, or other procedures. Surgery can work but is invasive, carries risk, and does not always solve the problem. Medications do not really exist.

That is where Nyxoah’s Genio comes in. If you can electrically stimulate the muscles that keep your airway open, you sidestep the mask. You implant a small device under the skin of your chest, run a thin wire up to your collarbone, and when you fall asleep it gently zaps the nerve that controls those muscles, keeping your airway patent. You wake up well-rested. No mask. No wires dangling across your pillow.

How Genio works

The technology rests on a well-understood principle: electrical stimulation of the right nerve can activate muscles. The challenge is identifying the right target (which nerve) and the right timing (when to deliver the pulse during the sleep cycle) and the right intensity (strong enough to work but not so strong it wakes you up or causes pain).

Nyxoah settled on hypoglossal nerve stimulation. The hypoglossal nerve runs from your brain down the side of your neck and controls the tongue and muscles in the upper airway. When you stimulate it, those muscles contract and stiffen, keeping the airway open.

Genio is small—roughly the size of a cardiac pacemaker—and uses similar implant technology. The device sits under the collarbone. A thin wire runs to the hypoglossal nerve. At night, a sensor detects your respiratory effort (the machine can tell you are trying to breathe but your airway is blocked). When that happens, Genio delivers a timed electrical pulse that makes the airway muscles contract. Problem solved. You breathe freely.

The device has a rechargeable battery and is programmed via an external remote. A doctor implants it under light sedation, a procedure that takes a couple of hours. Recovery takes a few weeks.

Regulatory approval and early commercial traction

Nyxoah went public in 2016 via a listing on the Nasdaq and has spent the years since securing regulatory approval and building the commercial infrastructure to sell Genio. The company won FDA clearance in 2019 and began selling the device in the United States. It also pursued approvals in Europe and other major markets. By the mid-2020s, Genio was available in multiple countries and the company was recruiting doctors, training hospital teams, and working to build reimbursement pathways—the critical bridge between a cleared device and actual revenue from patient implants.

The commercial pitch is direct: better than CPAP because there is no mask, more targeted than surgery because the nerve stimulation is reversible, and effective for a specific subset of sleep-apnea patients (those who still have enough airway collapse to be helped by increased muscle tone but not so much damage that opening the airway alone is impossible).

The business and the risks

Nyxoah’s entire business is Genio. There is no second product line, no diversification. Revenue comes from implants: the upfront device cost when a patient gets the implant, and ongoing revenue from programming visits, battery replacements, and device upgrades over the patient’s lifetime.

The company faces several real risks. First is adoption. Even with FDA clearance, sleep-apnea patients and their doctors have to decide that Genio is better than CPAP or surgery or just suffering. That requires good clinical data (trials showing it works), widespread awareness among sleep specialists, and reimbursement agreements with insurance companies. All of those take time. Second is competition. Large medical-device makers (Philips, ResMed, others) have noticed sleep apnea and may develop competing approaches. Third is the simple fact that implanting a device is a bigger step than putting on a mask, so the patient pool is not everyone with sleep apnea—only those motivated enough or desperate enough or wealthy enough to choose surgery.

How Nyxoah makes money

Today, Nyxoah’s revenue depends entirely on the number of Genio implants it places each quarter and each year. The company is still investing in manufacturing, clinical trials, and sales infrastructure. Until implant volume reaches scale, revenue will likely not cover the company’s operating expenses. That is typical for early-stage medical-device companies, but it means Nyxoah must have enough capital reserves or access to new funding to survive until Genio adoption accelerates.

The path to profitability is clear in principle: scale up the number of implants, expand into new geographies, possibly develop next-generation devices or treatments for related conditions. But execution is everything. The company must prove its device is truly superior to existing options, build a sales force that convinces doctors and patients to adopt it, and win reimbursement at prices high enough to support ongoing research and profit.

How to research Nyxoah

Anyone curious about Nyxoah should start with the company’s annual 10-K filing (SEC CIK 0001857190) and quarterly earnings reports. Pay close attention to the number of implants placed per quarter and the geographic breakdown of revenue. Clinical-trial results—how many patients improved, how often the device works, any safety issues—are published in medical journals and are crucial to understanding whether Genio lives up to its promise. Competitor moves in the sleep-apnea space are worth tracking. And watch the reimbursement announcements: if major U.S. insurers or international health systems decide to cover Genio, that is a catalyst for growth. Like any medical-device company, Nyxoah’s stock moves on clinical news, regulatory events, and the pace of commercial adoption.